Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Letter of Intent with Darmiyan, Inc. to Explore Use of FDA De Novo Authorized BrainSee(R) AI Platform in Early Alzheimer's Disease Trial Design
Red Light Holland Reports Fiscal 2026 Audited Year-End Results and Provides Update on Rhelion Life Sciences
Red Light Holland Announces Corporate Rebrand to Rhelion Life Sciences Corp
